>> i totally agree. >> one last question. using you can address viruses -- >> if you can address viruses to treat cancer. do you have hope in that area? >> i will just say a word. triedy in which we have to approach cancer has many different avenues. small molecules, biologic antibodies, and of course more traditional things like radiation, surgery. the virus approach often is you are trying to arm the virus to specifically go after the cancer cells. often it is a virus you engineered. i think there have been advances in that regard, some of them in brain cancer, what not to the point where we can fully see how that is going to provide a major we want to use

against most cancers. >> there are many viruses being utilized to try to take advantage of differences in cancer cells versus normal cells , that viruses may replicate in cancer cells versus not replicating. this provides opportunities to really disrupt those cancer cells and lead to death of the , but as francis mentioned, this is not as effective as one would imagine on the basis of that particular approach and paradigm. however, those viruses that are new antigens, when combined with immune modulation may provide significant opportunities to train the immune system to recognize not only viral particles but bystander mutations that are occurring in the cancer cell, so it may really prime the immune system further. there is exciting work going on

with a particular engineered virus and brain cancer, which is showing impressive result that of patients. we need to understand why some patients are responding versus not. those are exciting opportunities. i think that estimate is going to need to be combined with other modalities to bring out the full potential. quest we're out of time. i want to thank you for such an out ofting -- >> we are time. i want to thank you for such an interesting discussion. >> coming up tuesday night at eight eastern, a look at the death penalty in the u.s. criminal justice system. and lawyer brian stephenson. his book is "just mercy." here is a preview. >> i remember being shocked.

i remember reading about who got executed and who didn't and how the criminal justice system works. one of the things is when you write a book, you do research. i learned about police brutality , but also when slavery was abolished in the 13th amendment, it was, except for those who are imprisoned or indentured servants. it has not been abolished completely in this country. i have been amazed. it is the racism in the supreme court. they did an extensive study in itrgia about how torwhelmingly corresponds

when the victim is white. is athe victim is black it blip on the radar screen. when someone in st. thomas was killed, you are lucky you can five lines on page 30. almost always it was formulaic drug deal gone bad. when a white person was killed, it is always on the front pages of the paper. >> they start representing children prosecuted as adults, and when i talk about this presumption of guilt or people or people of color are built with, that's one of the great challenges. like in brown children -- black or brown children were with this sense of guilt, and it follows them wherever they are going. we are suffering in new york. we are suffering in ferguson. we are suffering in states with stand your ground laws.

in court just sitting there to get ready for a hearing. it was the first time i have been in this courtroom. i was just sitting there waiting for the hearing to start, and the judge walked out, and the prosecutor walked out behind a judge. you go back out there in the hallway and wait until your defense lawyer gets here. i stood up and said, i am actually the lawyer. the judge says, you are the lawyer, and he started laughing. the prosecutor started laughing. i made myself laugh, too, because i didn't want to disadvantage my client. my client came, and it was a young white kid i was representing. >> that's a great reversal. >> we did the hearing, and

afterwards i was thinking, how exhausting this is. it is exhausting for a lot of roomse attorneys, court are not comfortable places. all of that rage gets directed at you. is even morets, it hostile. we have a criminal justice system that treats you better if you are rich and guilty than poor and innocent. when you stand with poor people you feel the inequality. >> our conversation on the death penalty and the criminal justice system airs tomorrow night at eight eastern here on c-span. the cancer innovation coalition hosted an event about the need for additional resources and support for cancer research. from commerce men

bobby scott of virginia, who is a cancer survivor. -- from congressman bobby scott of virginia, who is a cancer survivor. this is about an hour. >> on behalf of the foundation, our ceo, who is not in attendance, but sends his gratitude for your attendance, thank you for being with us today. country, 1600 people will die of cancer. every single day of this year, 1600 people will die of cancer. have hadnd, we will 585,720 people in the united

states who will succumb to cancer. our nation will have spent $201.5 billion in health care costs to fight cancer and to provide treatment to the $1.6 million -- 1.6 million americans who will be diagnosed with cancer this year. these statistics are not numbers. they are families. they are futures not realized, and they are failures. they are failures we all share as we have been waging this war on cancer that was declared 50 years ago. progress.de 2000, life8 and expectancy for cancer patients increased by four years, which translated to 23 million additional years of life and roughly $1.9 trillion in value added to the economy.

in an article entitled "an economic evaluation of the war on cancer." on behalf of every family in our nation who has mourned the loss of a loved one, thank you for being here today to listen and to learn about the work of the cancer innovation coalition through project innovation. cancer cures are born of innovation. you will be addressed by experts. they will include our first congressman robert scott, and i must say our dear congressman, whom i will formally introduce in a moment. the panel that will address you includes dr. edith mitchell, and heather.on, allow me to introduce each analyst to you briefly.

dr. edith mitchell is an oncologist, board certified in oncologymedicine and and a clinical professor at the .epartment of medicine an associate director for diversity programs and director of the center to eliminate cancer disparities for the sidney kimmel cancer center at jefferson. dr. mitchell has spent her medical career helping individuals in medically underserved areas. she has published more than 100 this united states. she is known throughout this country as a retired brigadier general. femalest figure general -- brigadiercan general female african-american

in the united states. in theeer is documented numerous awards she has received, from the military, from the association of cancer centers, so it is a privilege to have her also as a member of the scientific committee of the national patient advocate foundation to address you. john harrington is recently retired. he distinguished himself by the late great teams and producing outstanding results. he retired as a senior vice president and chief commercial officer for global oncology. he built a commercial team in cambridge, massachusetts and all of the regions with commercial oncology. ruby is to this role, he led the u.s. oncology business unit. since his retirement, --

previous to this role, he led the u.s. oncology business unit. board,ed on the advisory the concord care -- conquer cancer foundation. have, and saying we that is the patient never gets it wrong. the speaker you will certainly enjoy as well is heather. she is a graduate of american university and washington, d.c., and she now enjoys traveling to exotic locations around the world with her husband, jeff. she lives in maryland with her husband, son, and two rescued cats. her hobbies include vegetable gardens, sewing, and home decorating. of 2012, she was

diagnosed with stage four cancer following a craniotomy. my privilege to share with you. they have -- others have said there message to you -- their message to you via videotape. other representatives from the research community. it is a privilege to be able to introduce to you congressman robert c scott. he is currently serving his 11th term in congress. prior to that he served in the house of representatives in 70ginia as a delegate from until 88. the senate of virginia from 1983 until 1995.

he has distinguished himself in his career with a passion for health care initiatives, but he on the subcommittee for civil rights and civil liberties of all americans. as part of his commitment to the developing of universal health care for all and previous congresses, representative scott introduced the all healthy children act to ensure millions of children would be ensured. he likewise worked to get that same provision into the affordable care act. he is a man of compassion. he is the son of a physician, and it is a privilege to introduce to you are presented of scott. -- representative scott. [applause] >> thank you for your kind introduction, and thank you for all that you do. of the is the proud home

patient advocate foundation, and you have obviously used your experiences with your friends dealing with health care to help others. people are faced with many challenges of what choices in health care they will pursue and how to pay for those choices, and the patient advocate foundation has helped hundreds of thousands of people navigate the health care system. they are also a reliable through when we went that, and a lot of the provisions have your fingerprints on it. affordability so everybody can get health care. those with pre-existing no unfair, those with cancellation of coverage, no caps on benefits, but a cap on total out of pockets of people don't go bankrupt. even if they have insurance, they won't go bankrupt with co-pays and adaptable's.

fingerprintst of on the affordable care act. -- they won't go bankrupt with co-pays and deductibles. we are also home to many other cancer related institutions, one of which the hampton university proton treatment institute is with thest a handful cutting-edge surgery that exists only in a handful of centers across the country. we have the cancer center, one of only 68 cancer centers designated by the national cancer institute and is a vital resource for cancer research. both doing significant research in the area of cancer treatment. all of these entities will benefit greatly from groups like project innovation coalition and the positive impact they will have.

under the leadership of the patient advocate foundation, the project innovation coalition represents a movement which will ensure access to life-saving treatment and medical care. launched just this year, project innovation was born out of the release of the report securing innovation and help in cancer treatment, which identifies institutional and regulatory funding hurdles which are driving up costs and delaying new therapies, which will limit patient access to new treatment. as our speakers will know today, these obstacles are not insurmountable. investment,on and the federal government can and should be able to move in the right direction and increase access to life-saving treatments. the project innovation coalition will continue to show policymakers and other stakeholders why these improvements are so necessary.

one of the problems we have in addressing this is some of our legislators will have to change priorities. in the past few years, as has extended massive tax cuts, but at the sameat the same time, tht funding for the centers for disease control and other research areas. many states have decided not to expand medicaid to provide health care for hundreds of thousands of people. less state money than those that did not. saved state money and providing coverage for hundreds of thousands of their citizens. we've done a lot with the affordable care act. there is still a lot to do. i believe it is the work of the national patient advocate

foundation and product innovation will be key to changing priorities and informing how we can make improvements by facing patients that are facing expensive ways to treat chronic or life-threatening conditions like cancer. once again, i want to thank you for all you have done and all that your continuing to do to help patients face their critical health care choices. thank you very much. [applause] let me share that from this point forward, we will essentially have now an address from cancer leaders who are going to speak out to you via video. and immediately, dr. mitchell will come to the microphone and address you. john harrington, then heather will come to the microphone and address you. joel, thank you. ♪

>> we are losing our edge. primarily because most of the innovation has taken place outside of this country. researchfor conducting and especially clinical trials is going down. as a result of that, many clinical trials are being outside of the united states instead of inside the united states. we used to be the great engine of american innovation. finding homes in europe and new business models emerging in china and the far east. >> the urgency now is with more and more people being diagnosed. we need innovation in cancer prevention. we need innovation in more cancer treatments. largelylowdown is related to funding of younger

investigators. i think we are in danger of losing a generation of cancer researchers as we face this problem. >> not long ago, we had a woman presented with an incapacitating headache. she had metastatic cancer to the brain which was a life rat. weree time of surgery, we able to take her tissue and send it for molecular profiling so we can take advantage of these therapies. a mutation that allowed access to target therapy. she could take a very toxic pill and her disease has gone into remission. forward has been in using engineered measles virus to treat a disease. it we have seen a woman who had the disease become resistant to many kinds of therapy. remissionin complete

for months going on years. >> innovation of cancer therapies is crucial at this point because we are reaching the limitations of some of the traditional therapies. the horizons open that we haven't imagined before. and the way cancer can be treated. patients will have more access to treatment that can potentially cure their cancer. the tumors we treat continue to change so that when we develop a new treatment, the tumor can actually adapt to that treatment and overcome it. the approaches that overcome --t resistance >> that is how we have improved

outcomes in the last 10 to 20 years. it's not just curing cancer. nursing perspective, it's treating patients to normal functionality. of changing demographics and changes in diseases, we could fall behind. >> it is now our privilege to welcome dr. edith mitchell. >> nancy, thank you very much. congressman scott.

ladies and gentlemen, thank you for being here this morning. it is a privilege for me to speak about cancer innovations. this year marked the 50th anniversary of the american society of oncology. which, in 1964, seven people got together to discuss cancer innovations and how it could move forward. move forward to 2014. membersore than 35,000 and is one of the largest organizations to demonstrate cancer innovations. now, not only is co emphasizing its large membership, but it's emphasizing .ew cancer innovations and the new and innovative

technologies we are using and that show our patients can survive and live longer. will see theey years showing significant advances in overall cancer survivorship. the american cancer society just this year reported that there was a 20% decline in cancer deaths over the last two decades. it means that 1,340,400 deaths were eliminated and therefore, these people survived. in 1960 four, there were fewer than 3 million cancer survivors. in 2014, there are more than 14 million people in the united states living and having survived cancer. time.s an extraordinary

it's very important that we continue the innovation in cancer research. meeting, at the earlier this year, there were demonstrations of what have some of the important advances been that we have made over the last 50 years? one of the first was chemotherapy cures for hodgkin's lymphoma. which was first found in 1965. and since that time, prior to it was universally detrimental and cost that. the treatment was limited with radiation. today, more than 90% of patients with hodgkinson foam a are cured. -- hodgkin's lymphoma are cured.

-- thisical cancer vaccine against the hpv virus not only allows for treatment and cures for cervical cancer, but other cancers including head .nd neck cancers three, targeted drug transformations. targeted drug transformations -- theout with the fact fda approval of the drug means that patients who universally die from this leukemia are now cured of that disease. and not only has it been useful in the treatment of chronic leukemia, but they

have much better prognosis. and the idea of targeted drugs than the trans standard chemotherapy. these patients do not suffer as much. very important. advance forwas the the cure of testicular cancer. prior to 1977, when dr. lawrence einhorn put forth his regiment for treating testicular cancer, almost all patients with testicular cancer died in one year. move forward to 2014. almost every patient with testicular cancer not only survives five years, but they are cured of the disease. innovation showed all of these therapies allowed for our

patients to live longer. advance wasive powerful antinausea drugs to eliminate the side effects of cancer treatments. strides made tremendous . not only have we conquered vomiting from chemotherapy and other treatments, but also drugs to treat anemia. and other side effects of cancer have been demonstrated. and what we have, therefore, is a better quality of life for patients. ina result of our investment clinical cancer research, more people are surviving cancer than ever before in this country. two out of three people live at least five years after a diagnosis of cancer.

many are cured. cancer death rate has dropped more than 20% in this country over the last 20 years. the last two decades. are to continue this advancement for treating patients, and treating the side effects, we must continue the research. month, october, is breast cancer awareness month. let me tell you about some of the advancements in the treatment of breast cancer. not only do we have the radical mastectomy but breast conservation therapy is there ,nd is the standard now decreasing a lot of the side effects and consequences of massive surgery such as the mastectomy.

the receptor and other hormonal and molecular receptors for breast cancer has allowed for drugs that address those specific receptors, allowing for personalized medicine with drugs such as tamoxifen. found,moxifen was first it was given to everybody. now we know which patients are more likely to benefit from the drug. consequently, personalized medicine -- meaning, we can get the right drug for the right patient the first time. and that is very important. not only have targeted therapies , butssed breast cancer other cancers also. melanoma, lung cancer, and others. therefore, our innovative develop new treatment plans and it allows for more patients to survive.

not only treatment, but innovative technologies for diagnosing cancer such as computerized tomography or ct scans. mris, genemography, sequencing, and finding the gene and mutations for cancer so that we can address specifically those mutations, those changes that cause cancer growth and proliferation in each individual patient. have provided you some of the innovative technologies over the last 50 years that have allowed for patients in the united states. but not only in the united states, to live longer and survive cancer, and therefore, have a better quality of life. whether we talk about chemotherapy treatment,

research, patient care, the nausea vomiting drugs, the chemotherapy, the technology for so and diagnostic imaging that we can more accurately diagnose cancers, them a regular technology -- the molecular technology. how did this come about? it did not happen overnight. it happened through each of these milestones having resulted from careful, basic, laboratory research, rigorously conducted clinical trials, and these clinical trials are made possible by the funding of research and the participation of patients in these clinical trials. videove heard from the that many clinical trials are moved outside the united's aides. states.d

it's important we address clinical research and all the stakeholders involved collectively joined together to move forward in the research. include --lders collectively, we have to work together. legislative, scientific, clinical, policy and governmental, the administrative part, institutions of higher learning so that we are bringing newer and younger generations into the arena for treating patients. institutions, but patients and advocacy. all of us must work together to make the commitments to provide the resources that permit innovative research and clinical applications so that we can continue to say it is the legacy of those early scientists and clinicians that got together

must develop innovative technologies to take care of patients with cancer. so we must continue this legacy. increasing survivorship for cancer patients, improving the .uality of life so more individuals can survive cancer. i am urging everyone, let's get together. everybody has a role and we should all work together. yes, we can conquer cancer. thank you very much. [applause] >> dr. mitchell, representative

scott, nancy. thank you for the opportunity to share my thoughts on some of the important health care issues facing the patience of the world and also facing the research capabilities of the united's dates. that issue -- united states. that issue is making sure that they have funded medications of access to prolong the quality and longevity of human life. while there is a very important focus on health care coverage, expenditures, and financing that representative scott and congress have been working hard to accomplish, there is also a need that they are focused on as well. to ensure that the innovation system in the united's dates that has delivered so many breakthroughs for so many patients in this country and around the world, continues to be funded and understood. fortunate to develop these perspectives in terms of not only working in the united also afor 32 years, but

great opportunity to travel the world in a global oncology perspective. i have seen what has occurred most recently in the and around the world. united states and around the world. biotechnologythe council, or the patient association. and also with care delivery systems. in this room, your lives have been touched by cancer. i have lost many friends and family members and i am a cancer survivor myself. it is that they gives you a razor's edge. it is my believe this country is becoming complacent. becomen that can complacent with opposition as world leader and oncology care.

research and development, and in vance sent that have led to significant improvements to survival and patient care. decades of unprecedented success have left many feeling, "what else is new?" and, " why haven't they cured cancer?" the american society of clinical oncology which you have heard we notchell speak about, longer hear the facts as relates to the clinical and economic benefit of innovation. resonate ints still capitals, andate most importantly, with patients around the country? i maintain it certainly does. benefits -- the beneficiaries of survival is

increasing for many types of cancer. that includes breast, prostate,:, and lung cancers. which many of these were thought of as a death sentence. and now patients have real, tangible hope. was only 40 years ago when we were saying that cancer deaths were increasing by 4.7%. and now, in the most recent 22011,ng time from 2007 there has been a reduction. 2007-2011, there has been a reduction. birthdays had, anniversaries achieved by those patients suffering from cancer. survival rates have increased 58% since the mid-70's for childhood cancers. children that died most often, especially in leukemia. increase. now there are almost 15 million cancer survivors.

you will see many of them around the thanksgiving celebrations that you will enjoy next month. i hope that you give thanks to the innovation that helps to save these people's lives. the investment to courage and commitment, there are now more than 1000 medicines in development for cancer. the promise offers new hope for cancer patients the unlocking of the human genome project. i would maintain the right product for the right patient for the right outcome saving money as well. as nancy mentioned, you lose sight of the fact that since 1988 to 2000, 23 million years of life is granted back to cancer patients. $1.9 trillion from an economic perspective has been the improvement based upon cancer treatments. this is a global health success story funded by the united

states government. world-class cancer research and development centers, the biotechnical industries. with all of these positive outcomes, some facts are neither good -- heard nor understood. the spending on cancer medicines represent less than 1% of overall health care spending. on cancer medicines represent only 20% of cancer treatment. thealso, if you look at average price growth of cancer drugs and medicare part b, it's less than medical inflation due in large part to the lowering of generic products. insurance covers a lower percentage. a cancer patient might face a 4% out-of-pocket, but 7% for outpatient.

they now face up to 20% as it relates to pharmaceutical care. i retired, i attended an m.i.t. innovation former ceo the stated the fact that the science and promise of rate through has -- breakthrough has never been more exciting. but innovation has never been more challenging than ever. council does phenomenal job representing the ecosystem of health care in massachusetts. they mentioned the funding which you heard representative scott talk about it certainly has gone down. what that means for project projects -- venture firms. then, is the venture firm? a are part of an ecosystem and investing in fuel life science companies particularly at the

series a level of funding. it's down from the peak at 2007. it's hard to see how it's going to return. dramatically cutting the reimbursement had a chilling effect on companies and investors. they are working hard to show the class benefit. and what the meeting means in -- the affordable health care act brought many needed changes to health care coverage for teaching anditutions operating facing many difficult trade-offs. work ine opportunity to other countries. meet our topften investigators in china, the far east, portions of eastern europe. patients,ses, 70% of 70% of patients are enrolled in critical trials -- clinical

trials. they are from other countries. we should welcome the fact that more citizens of the globe are being involved in cancer research and better understanding patient needs. that type of recruitment doesn't represent the diversity of the american population that they need to serve. i ask you to think about that as well. i personally observe the national single-payer systems so that delayed access, while negotiating price and access nor neither patient focused fair. we are facing a health improvement system that is fundamentally changed. tomorrow, if you go out to look at a new automobile, you would not ask for the technology of the 60's. few of you would ask for three on my column and an iron dashboard with no seat belts.

you would not ask for a new computer based on cobalt and the system i remember being in college. is that what we are asking for now? what we are benefiting from innovationse the made in the 60's, 70's, and 80's. are we looking at a just good enough approach? we have invested a lot. we have seen progress. are we looking at cost containment systems that were neither designed for the benefit of cancer patients? swell-being'ses and --those involved in cancer innovation, i hope that you enjoy the thanksgiving day holidays. you, ask them what they hope for. they hope for the ability to

dance at their daughter's wedding and live a full and come the life. and the recognition that hope is found in the care of their physician and also in the medication they take. ask them if today's cancer researchers believe they have adequate funding for a 10 to 12 year journey. we are already woefully short on oncologist. what does this mean as a nation and the need for oncologists? see anally, if you do oncologist, ask them what their hopes are for the future. and ask yourself when you look across the table at your family , if facedoved one with a diagnosis of cancer, wouldn't you want the most innovative and personalized care for them so you can focus on their survival and not focus on

a suboptimal system? thank you. [applause] >> good morning. thank you all for being here as well. ago, i would never have imagined i would be speaking to a group like this. two years ago, i was lying in a hospital bed. two years ago, i had just been informed that the tumor in my gut was inoperable. two years ago, i was preparing to die. let me start at kind of the beginning. my first awakening with my cancer was following a seizure when i was ambulance to the hospital. visited myat i have primary care doctor but that was pretty much useless. i had headaches that would not stop. craniotomy.aving a

i had a mass on the right side of my brain that was affecting the motor skills of my left side. when that tumor was surgically removed, it was diagnosed as stage for metastatic cancer with an unknown primary. that tissue, however, was consistent with lung tissue. many visitsd were and tests. it was determined we would need to start chemo because they did find another mass in my stomach. my abdomen. we would start chemo shortly. the absolute highest dosage. we had to wean that down because it was too devastating on my blood cells. i never got sick and i never got nauseous. i was very bald and very scared. i was another victim of the killer cancer. were herded into an

infusion room of like patients, if you looked around that room, you realize cancer does not discriminate. old, all races, all genders, all ethnic groups. it feels like striking, you are in it. we sit there patiently while the doctors pumped chemotherapy into our bloodstream. we hope and trust that the practice will get us through this journey. unfortunately for me, after three rounds of chemotherapy, and a fourth because there was some confusion as to the reading of these and, there was minimal change in the side of my tumor. i talked to my oncologist and there were two other courses. we could follow surgery or genomic testing. genomic testing was new and may not be covered by insurance. we can toss the ball in the air

and see what happens. i opted to go with both. the first was the surgery. that was not successful. as that information was being relayed to me almost simultaneously, the results came in from genomic testing. result told me i had a met -- itication, multiple should react positively to a new drug. shortly thereafter, i began taking it and it was november 19, 2012. in january when i went for the rumor -- then, the tumor had shrunk 60%. in subsequent test, it is completely gone. it is due to a simple pill. i have tried to be as concise as i can going through these ups

and downs in the discrepancies and the inconsistencies. many failures and disappointments along the way. after genomic testing, the story becomes very short. i share my story with you today not because i enjoy living every moment of it but it's important to me that others be made aware of what is available. i was given the opportunity for genetic treatment. it genomic treatment. through that, we found a drug that specifically treat my cancer mutation. i am sure there are many more victims that benefit from this innovation. but they must be made aware. for some reason, that knowledge is not being disseminated to the patients. i don't know why.

it could be regulatory. it could be insurance. it could be government obstacles. i do know firsthand that it could save lives. other innovations may provide life-sustaining treatments. i can only address my treatment. genomic testing worked for me but a not work for all. it is time to start investing and educating with these new innovations in mind. perhaps even pastimes. science is moving rapidly. they need to change now. that can be up to you. i strongly believe with the help of science and government funding, all victims will be treated with genomic testing or some other sort of innovation. though a cure may remain elusive, the ability to live and thrive with cancer is certainly well within our reach.

i thank you for this opportunity. [applause] >> you have heard from the experts. to introduce you to the cancer innovation coalition and have you understand what its mission and its purpose is. and invite each of you in this room to become very engaged in helping us to find solutions so secure the future of innovation and cancer therapy. the cancer innovation coalition was established in january of 2014 by the national patient advocate foundation in collaboration with our colleagues from the nonprofit patient community. initially, the american cancer society friends of cancer research and the cancer's up or -- health care

providers, nurses, business leaders, pharmaceutical and biotech industry companies. our members number 65 national organizations. each committed to working successfully to secure the future of innovation and cancer therapy. the cancer innovation coalition will focus on legislative and regulatory tasks in 2015. there is a call later today with the members of the cancer innovation coalition. they will be finalizing their policy agenda for 2015. in the following three areas. there will be tremendous focus on what we need to do in the area of medical trials -- creative clinical trial designed and accelerated approval to trials. there will be tremendous focus on the need for dramatic --

genetic testing and continued advanced research in the field of genomics. be deliver ito focus in the area of transparency and access. as you know, the affordable care act has provisions that we shall cover clinical trials. however, absent regulatory definition through rulemaking on the main streets throughout america, we have very diverse interpretation. especially we look at the issue of transparency. in the affordable care act, we call for transparency. call for transparency that will not pose any form of discrimination. there are plans for developing pathways and they are in senting

incentivng-- physicians. it may be a good process. we don't know. but we think it can be an advantage. by definition, what is the process for how we determine a pathway? what options are you eliminating? we look at the work that we have ahead of us. we must understand better how the united states can handle cancer population annually of 3.2 million people by the time we get to the year 2030. we know that the fda has worked very deliberately in recent months to accelerate and expand its creative approach to clinical trial design.

if we look at the friends of cancer research initiative today in collaboration with the fda and multiple members of the pharmaceutical and biotechnology community, what we see is a collaboration that is new and different for the united states. we are leveraging lessons learned and we are leveraging resources across multiple frameworks. shortening the outcome of the trials from a nine year to 10 year wait that normally cost $1 billion to produce one new drug in the united's eighth to a time where we can cut those costs dramatically. there is regulatory guidance to

be able to move drugs to market more quickly in this united's eighth. we also know that in the united states, if we are to secure the ature of innovation, we have model we can look at in the united kingdom. the clinical trials in the united kingdom was at 3%. we don't have the money to continue this and we are losing our citizens to this disease called cancer. they have established the national nickel trial network where every single clinical trial is registered so that the public can get to that information. easy instructions on how to enroll. they couple that with the creation of the clinical trial if i havehrough which an interest in funding a clinical trial and you have an

interest in funding the same clinical trial, we can register with that body and we will be partnered together. introductions will be made. we have multiple trials in that country that include multiple manufacturers, nonprofit groups. they have been able to move their cruel and clinical trials since 2001 to 17% annually. it is a nation with sensitivity to the needs of its population. it is a nation that wants to embrace the future and make life better for everyone in this country moving forward. that isthat we can do to deal with securing innovation in the field of cancer. let's remove the statistics about the 70% of families that have a cancer diagnosis moving to bankruptcy within six months

of that diagnosis. let's get rid of that. let's get rid of the statistics that tell us we're not finding the success we need. as demand higher bars be set in the research community. and we have to those moving forward. you are in a position in the united states congress to work with us. to have introduced regulatory reform measures that can improve what we have currently in statute. a position in congress to introduce new legislation that perhaps canon incent more funding for our research bodies. we have lost 20% of funding to jobsederal agencies whose are to start the research at the bedside. that's where it begins. there is no one that can step forward and fill that gap.

when you combine the loss of 20% of revenue with the research funding of the federal government and the escape of capital to foreign markets, you can see where we are today. 70% of our clinical trial approvals are occurring overseas. 30% are accruing in the united states. it means we lose jobs, revenues, and the patient's that call us a patient advocate foundation are underinsured. they need options that are not at the market and need access to clinical trials. they are often denied that if it is operated in another country. through the cancer innovation coalition and project innovation, we will be moving forward with multiple regulatory and legislative acts in 2015. we want to partner with each of

you in this room. we need your ideas. that youour ideas represent and the community you represent. and the constituents in your own district so we can understand what is needed to achieve resolution. on february 11, we will be at the national press club and at that point, we will announce to america the blueprint of the cancer innovation coalition for the project innovation remedy, working with members of the united states congress and regulatory officials today. i am pleased to have the opportunity to give you a bit of academic background for the cancer innovation coalition and what we want to achieve through project innovation. we are going to take question and answers immediately after we hear from one additional group of experts, including dr. woodcock from the fda. we